Bengaluru-based Immuneel Therapeutics has successfully raised over Rs 100 crore in its Series B funding round. The investment round saw participation from new investors, including Singularity AMC, Rainmatter by Zerodha, and several High-Net-Worth Individuals (HNIs).
Funding Details and Investor Participation
The Series B round marks a significant milestone for the company, which specializes in developing innovative immunotherapies for cancer and other diseases. The funds raised will be utilized to accelerate clinical trials, expand research and development activities, and strengthen the company's operational capabilities.
Singularity AMC, a prominent asset management company, and Rainmatter by Zerodha, the investment arm of the fintech firm, have joined the round alongside a group of HNIs. Their participation underscores growing investor confidence in Immuneel's cutting-edge approach to cell therapy.
Company Background and Future Plans
Immuneel Therapeutics is known for its work in chimeric antigen receptor (CAR) T-cell therapy, a form of immunotherapy that modifies a patient's own immune cells to fight cancer. The company has been at the forefront of developing affordable and accessible cell therapies for the Indian market.
With the fresh capital, Immuneel aims to advance its pipeline of CAR-T therapies targeting various hematological cancers and solid tumors. The company also plans to scale up its manufacturing capabilities and build a robust supply chain to ensure wider patient access.
This funding round comes at a time when the global immunotherapy market is experiencing rapid growth, driven by increasing cancer incidence and advancements in personalized medicine. Immuneel's focus on cost-effective solutions positions it well to capture a significant share of this expanding market.
